MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of short-term
investments
$121,310K
Proceeds from exercise of
common stock options
$3,545K
Net cash provided by
(used in) investing...
$8,286K
Net cash provided by
financing activities
$3,545K
Canceled cashflow
$113,024K
Net decrease in
cash, cash...
-$506K
Canceled cashflow
$11,831K
Deferred revenue
$46,267K
Stock-based compensation
$9,269K
Depreciation
$469K
Purchases of short-term
investments
$112,751K
Purchases of property and
equipment
$273K
Net cash used in
operating activities
-$12,337K
Canceled cashflow
$56,005K
Accounts receivable
$35,000K
Net loss
-$24,361K
Accretion of discounts on
investments, net
$2,624K
Accrued expenses
-$2,030K
Accounts payable
-$1,612K
Prepaid expenses and
other current assets
$1,343K
Other long-term
assets
$1,336K
Operating lease
right-of-use assets and...
$36K
Back
Back
Cash Flow
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)
source: myfinsight.com